Adaptive Biotechnologies (NASDAQ:ADPT) Reaches New 52-Week High – Here’s Why

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) shares reached a new 52-week high during trading on Wednesday . The stock traded as high as $24.62 and last traded at $24.55, with a volume of 3291444 shares traded. The stock had previously closed at $23.11.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the company. JPMorgan Chase & Co. decreased their price objective on Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating for the company in a report on Wednesday, May 6th. Piper Sandler lifted their target price on Adaptive Biotechnologies from $20.00 to $27.50 and gave the company an “overweight” rating in a research note on Tuesday. BTIG Research lifted their price objective on shares of Adaptive Biotechnologies from $24.00 to $25.00 and gave the company a “buy” rating in a research report on Thursday, July 30th. Weiss Ratings restated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research note on Friday, July 17th. Finally, Morgan Stanley lifted their target price on shares of Adaptive Biotechnologies from $20.00 to $22.00 and gave the company an “equal weight” rating in a report on Thursday, July 30th. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $24.42.

Adaptive Biotechnologies Price Performance

The stock has a fifty day moving average of $20.20 and a two-hundred day moving average of $16.82. The stock has a market cap of $3.77 billion, a price-to-earnings ratio of -57.56 and a beta of 2.08. The company has a quick ratio of 4.68, a current ratio of 4.79 and a debt-to-equity ratio of 2.22.

Adaptive Biotechnologies (NASDAQ:ADPT) last issued its earnings results on Wednesday, July 29th. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.12). The company had revenue of $71.55 million for the quarter, compared to analysts’ expectations of $65.44 million. Adaptive Biotechnologies had a negative return on equity of 36.81% and a negative net margin of 20.73%.Adaptive Biotechnologies’s revenue for the quarter was up 21.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.17) earnings per share. On average, equities research analysts anticipate that Adaptive Biotechnologies Corporation will post -0.4 earnings per share for the current year.

Insider Activity at Adaptive Biotechnologies

In other Adaptive Biotechnologies news, insider Susan Bobulsky sold 11,000 shares of the stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $18.00, for a total value of $198,000.00. Following the completion of the transaction, the insider directly owned 416,775 shares of the company’s stock, valued at approximately $7,501,950. This trade represents a 2.57% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Sharon Benzeno sold 154,768 shares of the business’s stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $21.14, for a total value of $3,271,795.52. Following the sale, the insider directly owned 221,278 shares in the company, valued at $4,677,816.92. This trade represents a 41.16% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 1,307,086 shares of company stock valued at $27,859,739. 5.70% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. Caitong International Asset Management Co. Ltd purchased a new position in Adaptive Biotechnologies during the 4th quarter valued at about $28,000. EverSource Wealth Advisors LLC raised its position in shares of Adaptive Biotechnologies by 197.1% during the 4th quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock worth $38,000 after purchasing an additional 1,565 shares during the last quarter. Assetmark Inc. raised its position in shares of Adaptive Biotechnologies by 867.9% during the 4th quarter. Assetmark Inc. now owns 3,020 shares of the company’s stock worth $49,000 after purchasing an additional 2,708 shares during the last quarter. T. Rowe Price Investment Management Inc. purchased a new stake in Adaptive Biotechnologies in the 4th quarter valued at approximately $51,000. Finally, Strive Financial Group LLC acquired a new stake in Adaptive Biotechnologies during the 4th quarter valued at $52,000. Hedge funds and other institutional investors own 99.17% of the company’s stock.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.